[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585797":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":186,"collaborators":188,"id":191,"slug":192,"hasResults":193,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":193,"sex":199,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":20,"studyType":205,"phases":206,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},{"fullName":5,"class":6},"Eikon Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1","EXPERIMENTAL","EIK1004 (IMP1707) monotherapy; oral tablet(s) daily (except for the single-dose period). Participants will receive escalating doses of EIK1004 (IMP1707) until progressive disease or discontinuation.",[13],"Drug: EIK1004-001 (IMP1707-001)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","EIK1004-001 (IMP1707-001)","PARP1 selective inhibitor",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Yawei Zhang, MD","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Sunny Chaudry, MS","CONTACT","6319026200","chaudrys@eikontx.com",[32,51,66,81,96,110,125,142,159,174],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Sarah Cannon Research Institute at HealthOne","RECRUITING","Denver","Colorado","80218","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-104.9847,39.73915,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":20,"email":50},"Shelby Mosier-Murray","720-701-0123","Shelby.MosierMurray@sarahcannon.com",{"facility":52,"status":34,"city":53,"state":54,"zip":55,"country":38,"countryCode":39,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Florida Cancer Center","Lake Mary","Florida","32746",{"type":41,"coordinates":57},[58,59],-81.31784,28.75888,{"lat":59,"lon":58},[62],{"name":63,"role":28,"phone":64,"phoneExt":20,"email":65},"Alexander Philipovskiy","407-804-6133","alexander.philipovskiy@flcancer.com",{"facility":67,"status":34,"city":68,"state":69,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Beth Israel Deaconess Medical Center","Boston","Massachusetts","02215",{"type":41,"coordinates":72},[73,74],-71.05977,42.35843,{"lat":74,"lon":73},[77],{"name":78,"role":28,"phone":79,"phoneExt":20,"email":80},"Gary Barahona","617-975-7474","gbaraho1@bidmc.harvard.edu",{"facility":82,"status":34,"city":83,"state":84,"zip":85,"country":38,"countryCode":39,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"MD Anderson","Houston","Texas","77030",{"type":41,"coordinates":87},[88,89],-95.36327,29.76328,{"lat":89,"lon":88},[92],{"name":93,"role":28,"phone":94,"phoneExt":20,"email":95},"Cindy Bang","877-632-6789","cbang@mdanderson.org",{"facility":97,"status":34,"city":98,"state":84,"zip":99,"country":38,"countryCode":39,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"NEXT Oncology","San Antonio","78229",{"type":41,"coordinates":101},[102,103],-98.49363,29.42412,{"lat":103,"lon":102},[106],{"name":107,"role":28,"phone":108,"phoneExt":20,"email":109},"China Whitwer","210-580-9500","cwhitwer@nextoncology.com",{"facility":111,"status":34,"city":112,"state":113,"zip":114,"country":38,"countryCode":39,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"NEXT Virginia","Fairfax","Virginia","22031",{"type":41,"coordinates":116},[117,118],-77.30637,38.84622,{"lat":118,"lon":117},[121],{"name":122,"role":28,"phone":123,"phoneExt":20,"email":124},"Nicole Bryson","703-783-4510","nbryson@nextoncology.com",{"facility":126,"status":34,"city":127,"state":128,"zip":129,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"PASO Medical","Frankston","Victoria","3199","Australia","AU",{"type":41,"coordinates":133},[134,135],145.12291,-38.14458,{"lat":135,"lon":134},[138],{"name":139,"role":28,"phone":140,"phoneExt":20,"email":141},"Vinod Ganju","397815244","vg@paso.com.au",{"facility":143,"status":34,"city":144,"state":145,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Chongqing University Cancer Hospital","Chongqing","Chongqing Municipality","400030","China","CN",{"type":41,"coordinates":150},[151,152],106.55771,29.56026,{"lat":152,"lon":151},[155],{"name":156,"role":28,"phone":157,"phoneExt":20,"email":158},"Yongsheng Li-PI","023-65311341","yongshengli2005@163.com",{"facility":160,"status":34,"city":161,"state":162,"zip":163,"country":147,"countryCode":148,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)","Jinan","Shandong","250117",{"type":41,"coordinates":165},[166,167],116.99722,36.66833,{"lat":167,"lon":166},[170],{"name":171,"role":28,"phone":172,"phoneExt":20,"email":173},"Yuping Sun","0531-67626073","13370582181@163.com",{"facility":175,"status":34,"city":176,"state":20,"zip":20,"country":147,"countryCode":148,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Fudan University Shanghai Cancer Center","Shanghai",{"type":41,"coordinates":178},[179,180],121.45806,31.22222,{"lat":180,"lon":179},[183],{"name":184,"role":28,"phone":20,"phoneExt":20,"email":185},"Yunyan Guo","guoyunyan@solemed.com.cn",{"type":187,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[189],{"name":190,"class":6},"Impact Therapeutics, Inc.","100585797","phase-1-a-study-of-parp1-selective-inhibitor-eik1004-imp1707-in-participants-with-advanced-solid-tumors-100585797",false,"NCT06907043","A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","A Phase 1\u002F2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors","EIK1004-001","• Breast cancer: must have received at least one prior chemotherapy in neoadjuvant\u002Fadjuvant\u002Fmetastatic setting, must have received hormonal therapy if HR+, HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease.\n\nmCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy; Pancreatic cancer, must have prior 1L therapy\n\n* Age ≥ 18 years at the time of informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n* Adequate organ function\n* Life expectancy ≥ 12 weeks\n* Should have evaluable disease as defined by RECIST1.1 and\u002For CA125 or PSA\n* Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of EIK1004 (IMP1707)\n* Deleterious or suspected deleterious germline or somatic mutations of select HRR genes\n* Up to 1 prior line of PARP inhibitor containing treatment\n\nCNS Inclusion Criteria:\n\n* Untreated CNS metastases (measurable and\u002For non-measurable) not needing immediate local therapy.\n* Previously treated CNS metastases\n\nKey Exclusion Criteria:\n\n* Any investigational or approved anti-cancer therapies administered within 28 days\u002F before the first dose of EIK1004 (IMP1707)\n* Have received prior PARP1 selective inhibitors\n* Mean resting QTcF \\> 470 ms or QTcF \\\u003C 340 ms\n* Infections\n\n  \\- An active hepatitis B\u002FC infection\n* Any known predisposition to bleeding\n* Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability\n\nCNS Exclusion Criteria\n\n* Any untreated brain lesions \\> 2.0 cm in size.\n* Ongoing use of systemic corticosteroids for control of symptoms of CNS metastases \\\u003C 7 days prior to the first dose of study treatment or requirement for \\> 10 mg prednisone\u002Fday.\n* Any brain lesion requiring immediate local therapy, including (but not limited to) a lesion in an anatomic site where an increase in size or possible treatment-related edema may pose risk to the participant (eg, brain stem lesions).\n* Known, symptomatic leptomeningeal disease.\n* Have poorly controlled seizures.","ALL","18 Years","89 Years",{"count":203,"type":204},130,"ESTIMATED","INTERVENTIONAL",[207,208],"PHASE1","PHASE2","This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced\u002Fmetastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious\u002Fsuspected deleterious mutations of select homologous recombination repair (HRR) genes.\n\nCondition or disease Intervention\u002Ftreatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1\u002FPhase 2",[211],"Advanced Solid Tumors",[213,214,215,216,217,218,219],"EIK1004","IMP1707","Advanced\u002Frecurrent\u002Fmetastatic pancreatic adenocarcinoma","Brain metastases","Advanced HER2-negative breast adenocarcinoma","Recurrent HER2-negative breast adenocarcinoma","metastatic HER2-negative breast adenocarcinoma","2025-08-18",{"date":222,"type":223},"2025-08-19","ACTUAL",{"date":225,"type":223},"2025-04-30",{"date":227,"type":204},"2028-12",{"name":5,"class":6},10]